We are currently witnessing a dramatic shift in our approach to the treatment of B-cell non-Hodgkin lymphoma (B-NHL). In the evolving clinical landscape, novel treatments for this clinically heterogeneous disease span a wide range of interventions, encompassing targeted agents, cell therapy approaches, and novel monoclonal antibodies (NMABs). Among these, the latter are likely to exert the most profound impact due to their distinctive high efficacy and versatile applicability. NMABs represent a heterogeneous group of agents, including naked antibodies, immunotoxins, and T-cell-engaging molecules. In recent times, several NMABs have either gained regulatory approval or are on the verge of introduction into clinical practice, addressing multiple therapeutic indications and treatment regimens. Their anticipated impact is expected to be broad, initially in the context of relapsed/refractory (R/R) disease and subsequently extending to early treatment lines. The scope of this review is to provide a comprehensive overview of the biological characteristics, clinical properties, efficacy, and toxicity profiles of NMABs that have recently been introduced or are nearing integration into clinical practice.
当前，我们正见证B细胞非霍奇金淋巴瘤（B-NHL）治疗策略的深刻变革。在这一不断演进的临床格局中，针对这种临床异质性疾病的创新疗法涵盖了广泛的干预手段，包括靶向药物、细胞疗法以及新型单克隆抗体（NMABs）。其中，新型单克隆抗体因其独特的高效性和广泛适用性，预计将产生最为深远的影响。这类抗体包含多种类型，如裸抗体、免疫毒素和T细胞衔接分子。近年来，已有数种新型单克隆抗体获得监管批准或即将投入临床实践，适用于多种治疗指征和方案。预计其影响范围将十分广泛，初期将主要应用于复发/难治性（R/R）疾病，随后逐步扩展至早期治疗阶段。本综述旨在全面概述近期已投入或即将进入临床实践的新型单克隆抗体的生物学特性、临床特征、疗效及毒性反应。
肿瘤(癌症)患者之家